FDA Approves Targeted Therapy for Solid Tumors with NTRK Gene

2018-11-27T14:40:07+00:00November 27th, 2018|Hot Topics, News|

Tuesday, November 27, 2018 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with advanced solid tumors, including lung cancer, that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance mutation. These gene fusions can be in the NTRK1, NTRK2, or NTRK3 genes. Patients with advanced lung cancer who had NTRK gene fusions were included in the research that led to this [...]

FDA Approves Tagrisso as First-line Treatment for NSCLC

2018-04-23T13:55:25+00:00April 19th, 2018|Hot Topics, News|

Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa). Up until this point, Tagrisso was approved as a second-line treatment [...]